Body Mass Index and Cognitive Decline in Mild Cognitive Impairment

Benjamin B. Cronk, MS*, David K. Johnson, PhD†, Jeffrey M. Burns, MD*, and the Alzheimer’s Disease Neuroimaging Initiative

*Department of Neurology, University of Kansas School of Medicine, Kansas City
†Department of Psychology, University of Kansas, Lawrence, KS

Abstract

Objective—To examine the relationship between body mass index (BMI) and cognitive decline in subjects diagnosed with mild cognitive impairment (MCI).

Methods—Neuropsychologic and clinical evaluations were conducted at baseline, 6-months, and 1-year on 286 MCI subjects enrolled in the Alzheimer’s Disease Neuroimaging Initiative. A global cognitive composite score was derived (mean Z-score) from performance on 9 neuropsychologic subtests. Height and weight were assessed at baseline and used to calculate BMI. Generalized estimating equations (linear and logistic) assessed the relationships of baseline BMI with cognitive outcomes, clinician judgment of “clinically significant decline” over 1-year, and diagnostic progression from MCI to Alzheimer disease.

Results—Lower baseline BMI was associated with significant declines in cognitive performance in individuals with MCI over 1 year (Mini-Mental State Examination, Alzheimer Disease Assessment Scale-Cognitive subscale, and a global cognitive composite; all \( P < 0.05 \)). We observed a significant protective effect of baseline BMI in reducing the risk of a clinically significant decline in Alzheimer Disease Assessment Scale-Cognitive subscale and mini-mental state examination \( (P < 0.05) \). No association was found between BMI and changes in the clinical dementia rating sum of boxes or conversion to Alzheimer disease.

Conclusions—Lower baseline BMI is associated with more rapid cognitive decline in MCI. This relationship suggests either body composition may influence the rate of cognitive decline in MCI or factors related to MCI influence body composition.

Keywords
mild cognitive impairment; Alzheimer disease; body weight; body composition; body mass index; cognitive decline

Higher body mass index (BMI) in midlife is associated with structural brain changes,\(^1,2\) cognitive decline,\(^3\) and an increased risk of Alzheimer disease (AD)\(^4\) in late life. Accumulating evidence suggests, however, that the relationship between BMI and cognitive...
outcomes is attenuated, and perhaps reversed, by age. In longitudinal studies of older adult populations (generally aged 65 y and above), low BMI is associated with an increased risk of developing dementia, whereas high BMI is associated with a lower risk of dementia. In addition, weight loss is associated with an increased risk of dementia suggesting it may be a risk factor or an early sign of AD. This is consistent with multiple studies demonstrating that weight loss is present several years before the onset of clinically recognizable AD symptoms.

Mild cognitive impairment (MCI) is characterized as a transition phase between normal aging and AD with 10% to 15% of MCI patients progressing to overt AD annually. There is little prospective data on body composition in MCI. Thus, we examined the relationship between BMI and cognitive decline in individuals with MCI enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). We hypothesized that low BMI in MCI is a marker of preclinical AD and would be associated with more rapid cognitive decline and higher rates of progression to AD.

METHODS

Sample

All participant data were obtained from the ADNI database (www.loni.ucla.edu/ADNI). ADNI is an ongoing 5-year, 50 site, public-private cooperative partnership conducted by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and nonprofit organizations (PI: Michael W. Weiner, MD, VA Medical Center and University of California, San Francisco). Its primary goal is to test whether serial magnetic resonance imaging, positron emission tomography, other biologic markers, and clinical and neuropsychologic assessment can be combined to measure the progression of MCI and AD. The current report used all of the available clinical and neuropsychologic data collected at baseline, 6, and 12-month follow up (data available as of February 5, 2008).

Two hundred eighty-six ADNI participants diagnosed with MCI were included. MCI diagnostic criteria included Mini-Mental State Examination (MMSE) scores between 24 and 30, a memory complaint, objective memory loss measured by education adjusted scores on Wechsler Memory Scale (WMS) Logical Memory II, a clinical dementia rating (CDR) of 0.5, absence of significant levels of impairment in other cognitive domains, essentially preserved activities of daily living, and an absence of dementia.

Clinical Assessment

Standard clinical and neuropsychologic evaluations (common to all ADNI sites) were performed at baseline, 6, and 12-months including a CDR and battery of 2 cognitive screening instruments and 9 neuropsychologic tests (MMSE, Alzheimer Disease Assessment Scale-Cognitive subscale (ADAS-Cog), WMS-Revised Logical Memory I and II, Auditory Verbal Learning Test, Boston Naming Test, Trail Making A and B, Digit Symbol, Clock Drawing Test, and Category Fluency). We used height and weight measures to calculate BMI (kg body weight/m² height). After clinical evaluation and review of medical history, CDR, neuropsychologic performance, and laboratory tests evaluating clinicians rendered diagnosis consistent with National Institute of Neurological Disorders and Stroke/Alzheimer Disease and Related Disorders Association criteria for each participant (normal, MCI, AD; ADNI protocol available at http://www.adni-info.org). Cognitively normal participants had MMSE scores between 24 and 30 (inclusive), a CDR of 0, were nondepressed, non-MCI, and nondemented. Participants diagnosed with MCI had MMSE scores between 24 and 30 (inclusive), a memory complaint and objective memory loss measured by education-adjusted
scores on WMS-Revised Logical Memory II, a CDR of 0.5, largely preserved activities of
daily living, and an absence of dementia. Participants diagnosed with AD had MMSE scores
between 20 and 26 (inclusive), CDR of 0.5 or 1.0, and met National Institute of
Neurological Disorders and Stroke/Alzheimer Disease and Related Disorders Association
criteria for probable AD. All data records were reviewed by a Central Review Committee to
insure the uniform application of eligibility and diagnostic criteria across sites (including
conversion from MCI to AD).

Cognitive Outcomes

We used 4 summary scores to index global cognitive performance: MMSE,\textsuperscript{13} ADAS-Cog,\textsuperscript{14} CDR sum of boxes,\textsuperscript{15} and a global Z-score composite derived by averaging standard scores
within an individual across all 9 subtests of the ADNI neuropsychologic battery (Logical
Memory II, Digit Span Forward, Digit Span Backward, category fluency animals, category
fluency vegetables, Trail Making B, Boston naming test, Auditory Verbal Learning test, and
Digit Symbol). The MMSE is a brief cognitive impairment-screening instrument. ADAS-
Cog is a slightly longer cognitive impairment instrument used frequently in clinical trials.
The CDR assesses cognitive function along 5 levels of impairment (rated as 0, 0.5, 1, 2, or
3) in each of 6 domains: memory, orientation, judgment and problem solving, community
affairs, home and hobbies, and personal care. CDR sum of boxes is the sum of the ratings in
each of the 6 domains.

In follow up assessments, 3 of these quantitative measures (ADAS-Cog, MMSE, and the
CDR sum of boxes scores) were rated by the clinician as representing either a “clinically
significant or nonsignificant” decrement in performance (relative to the participant’s
previous assessment; yes or no). Given the entire clinical-cognitive profile of each
participant, the evaluating clinician also rendered a diagnostic appreciation whether that
individual had progressed from MCI to dementia (yes or no). As per the ADNI protocol, the
threshold for “clinically significant” was left to the judgment of the ADNI physician.

Statistical Analyses

Generalized estimating equations\textsuperscript{16} (GEE; SPSS 15, 1 tailed $\alpha<0.05$) were used to assess the
relationship between all cognitive outcomes and baseline BMI, controlling for age, sex, and
education. GEE is a repeated measures regression that additionally accounts for serial
autocorrelation of test scores over time (within-subject). Dependent variables included the 4
quantitative indices of global cognition and the 5 binomial qualitative appreciations of
clinically significant change from prior assessment. For quantitative outcomes linear GEE
was used. For qualitative (binomial) outcomes logistic GEE was used. In all analyses,
predictor variables included baseline BMI, time, and a BMI by time interaction. Resultant
slope estimates reflect the influence of baseline BMI on cognition over time. GEE analyses
included all 3 time points (baseline, 6, and 12 mo), thus using all available data to maximize
statistical efficiency whereas also controlling for any existing baseline differences in
performance. For all GEE analyses, we used a model fitting technique described in Singer
and Willett\textsuperscript{17} to determine which of 4 within-subject correlation structures (independent,
exchangeable, autoregressive, and unstructured) best represented the autocorrelation of the
MCI participant scores. The exchangeable correlation structure best fit both the linear and
binomial data.
RESULTS

Sample Characteristics
The MCI cohort (N=286) had a mean BMI of 26.0 (SE=4.0), age of 75.0 years (SE=7.5 y), and education of 15.8 (SE=3.0); 34.3% were female (n=98). Cognitive outcome characteristics for the ADNI MCI cohort are reported in Table 1.

Relationship of BMI to Cognitive Performance
Results from the linear GEE analyses (adjusted for age, education, and sex) indicate that although BMI was not associated with cognitive performance at baseline, lower BMI (at baseline) was associated with an increased rate of cognitive decline in MMSE (Wald $X^2=15.4$, df=2; $P<0.001$), ADAS-cog (Wald $X^2=6.7$, df=2; $P=0.02$), and the global composite (Z-score; Wald $X^2=8.2$, df=2; $P=0.02$) over the 3 assessments in the 1-year study period (baseline, 6, and 12 mo). No association was observed between baseline BMI and change in CDR sum of boxes over the 12-month follow-up (Wald $X^2=3.5$, df=2; $P=0.17$). Inspection of Table 1 reveals that most of the cognitive decrement occurred at the 6-month follow-up and then persisted at relatively constant levels in the 12th month. Figure 1 graphically represents the relationship between baseline BMI and 1-year change in global cognition. Tertiles of BMI participant data were plotted against cognitive performance over time (adjusted for covariates). Across all 3 measures presented, less cognitive decline is apparent in the highest BMI tertile compared with participants in the lowest baseline BMI tertile.

Baseline BMI and Clinically Significant Cognitive Change
Results from the logistic GEE adjusted for age, education, and sex show a protective effect of higher BMI. Higher BMI is associated with lower rates of declining cognitive scores in both MMSE [odds ratio (OR)=0.93; confidence interval (CI)=0.86–1.00; $P=0.03$] and ADAS-Cog performance (OR=0.91; CI=0.83–0.99; $P=0.02$). No association was found between BMI and CDR Box Score (OR=0.98; CI=0.91–1.05; $P=0.27$) or between BMI and diagnostic progression to AD (OR=0.98; CI=0.92–1.05; $P=0.31$).

DISCUSSION
This assessment of 286 MCI participants enrolled in ADNI suggests that lower BMI at baseline is associated with increased rates of cognitive decline over 1 year as measured by the MMSE, ADAS-Cog, and a global composite score derived from the ADNI neuropsychologic battery. Lower BMI was also associated with increased risk of clinically significant decline on the MMSE and ADAS-cog suggesting that these associations are clinically recognizable and important. The data indicate that BMI remained stable through this short follow-up whereas cognition declined, suggesting that low BMI predisposes an individual to more rapid disease progression. Alternatively, factors associated with MCI and cognitive decline may influence body composition. Longer follow-up with time-lagged or change-score designs in the ADNI sample is warranted to investigate the causal relationship between weight loss and cognition.

BMI is a commonly used measure of adiposity that is associated with adverse health outcomes including mortality,\textsuperscript{18–20} cardiovascular disease,\textsuperscript{21–23} diabetes,\textsuperscript{24} and hypertension.\textsuperscript{25,26} Several longitudinal studies have demonstrated that lower BMI at baseline and loss of BMI over time is associated with an increased risk of developing AD.\textsuperscript{10,11,27,28} Individuals who develop dementia have weight loss in the 4 to 10 years leading up to diagnosis with accentuation of this weight loss at the time of diagnosis, depending on diagnostic criteria.\textsuperscript{10,11} Although clinical studies suggest that weight loss may be present in
the clinical and preclinical stages of AD, autopsy data suggests that the loss of BMI in older adults may be in part related to the accumulation of AD pathology.29 In a clinical-pathologic study of 298 individuals, BMI in the years before death was associated with AD pathologic burden, even in nondemented individuals.29 As many, if not most, individuals with MCI are in the earliest clinical stages of AD,30,31 our data is consistent with prior studies suggesting that decreased BMI may be an early systemic manifestation of the AD process.10,27,28 In this study, however, BMI did not predict progression to a diagnosis of AD, although the power to assess this relationship is limited by the small number of individuals progressing to AD (n=54) over the short time frame (1 y). This issue is likely compounded by the subjectivity of the diagnostic appreciation across centers and individual clinicians.

Although MCI is a heterogeneous condition and can be related to static or reversible causes (ie, depression, medications, and medical illness), the MCI criteria identify a population enriched with individuals in the earliest clinical stages of AD. Although our analyses did not demonstrate increased rates of progression to overt clinical AD, the relationship between BMI and cognitive decline is consistent with prior studies suggesting that AD neuropathology, which likely begins accumulating years before the clinical onset, may be in part responsible for lower BMI.27 Greater atrophy in the medial temporal lobe in AD is associated with lower BMI suggesting that brain change and body weight occur in tandem.32 Psychosocial hypotheses for weight loss such as behavioral changes influencing caloric intake (forgetting to eat or the inability to plan and prepare adequate meals) are possible, although the studies suggest against this possibility10,33 and MCI participants have limited functional changes.

This study is limited by a short follow up period of 1 year attenuating our power to assess the impact of BMI on cognitive decline in MCI and subsequent progression of MCI to AD. Although the overall effect reported here is modest, the time period measured is short (1 y) and given the likelihood of cumulative cognitive decrements, the long-term clinical impact on cognition may be severe. Thus, the findings reported here are confined to associations with the baseline BMI and not with change in BMI over time. In addition, BMI does not differentiate the contributions from muscle mass and body fat; thus, low BMI may reflect reductions in muscle mass, fat mass, or both. Further differentiating the role of body composition using more sensitive measures that differentiate components of body composition may be important given that muscle and fat are metabolically different and have different risk implications. Future studies should explore the use of more sophisticated measures of body composition to characterize the individual relationships of lean mass and fat mass on cognitive decline through time.

Acknowledgments

This study was supported by the National Institute on Aging (K23 NS058252). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI; Principal Investigator; Michael Weiner; NIH grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and through generous contributions from the following: Pfizer Inc, Wyeth Research, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck & Co Inc, AstraZeneca AB, Novartis Pharmaceuticals Corporation, Alzheimer’s Association, Eisai Global Clinical Development, Elan Corporation plc, Forest Laboratories, and the Institute for the Study of Aging, with participation from the US Food and Drug Administration. Industry partnerships are coordinated through the Foundation for the National Institutes of Health. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of California, Los Angeles.
References


**FIGURE 1.**
Predicted means of cognitive outcomes and BMI in tertiles at baseline and 1-year follow up for mild cognitive impairment participants. The predicted means of cognitive outcomes are presented for tertiles of BMI adjusted for age, education, and sex. Lower scores represent worse performance for the global composite score and Mini-Mental Status Examination (MMSE), whereas higher scores represent decline in clinical dementia rating (CDR) sum of boxes and Alzheimer Disease Assessment Scale-Cognitive subscale. Less cognitive decline over 1-year is apparent in the highest BMI tertile across the measures. BMI indicates body mass index.
### TABLE 1
Characteristics of MCI Subjects at Baseline, 6, and 12 Months (N = 286)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>6 mo Follow-up</th>
<th>12 mo Follow-up</th>
<th>“Clinically Significant” Change (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg body weight/m² height)</td>
<td>26.0 (4.0)</td>
<td>26.1 (4.2)</td>
<td>26.0 (4.0)</td>
<td>—</td>
</tr>
<tr>
<td>MMSE (range: 0 to 30)</td>
<td>26.9 (1.8)</td>
<td>26.5 (2.6)</td>
<td>26.6 (2.5)</td>
<td>70</td>
</tr>
<tr>
<td>ADAS-Cog (range: 0 to 70)*</td>
<td>9.5 (3.7)</td>
<td>14.5 (3.2)</td>
<td>14.9 (3.6)</td>
<td>54</td>
</tr>
<tr>
<td>CDR Box Score (range: 0 to 18)*</td>
<td>1.6 (0.9)</td>
<td>1.8 (1.1)</td>
<td>1.9 (1.2)</td>
<td>86</td>
</tr>
<tr>
<td>Global composite (Z-score, −1 to +1)</td>
<td>−0.97 (0.6)</td>
<td>−0.89 (0.68)</td>
<td>−0.91 (0.71)</td>
<td>—</td>
</tr>
<tr>
<td>Diagnostic progression from MCI to AD</td>
<td>—</td>
<td>n=15</td>
<td>n=30</td>
<td>54</td>
</tr>
</tbody>
</table>

Clinically significant change was assessed by ADNI clinicians for MMSE, ADAS-cog, CDR scores (yes or no). Data presented represents the number of subjects deemed to have significant change in these tests or progressing to a diagnosis of AD.

* Reverse scored: less impaired to more impaired performance, otherwise high scores indicate better performance.

AD indicates Alzheimer disease; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; ADNI, Alzheimer’s Disease Neuroimaging Initiative; BMI, body mass index; CDR, clinical dementia rating; MCI, mild cognitive impairment; MMSE, Mini-Mental Status Examination.